Suppr超能文献

新型肌肽制剂的治疗潜力:药物开发前景

The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development.

作者信息

Bonaccorso Angela, Privitera Anna, Grasso Margherita, Salamone Sonya, Carbone Claudia, Pignatello Rosario, Musumeci Teresa, Caraci Filippo, Caruso Giuseppe

机构信息

Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy.

NANOMED-Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, University of Catania, 95125 Catania, Italy.

出版信息

Pharmaceuticals (Basel). 2023 May 23;16(6):778. doi: 10.3390/ph16060778.

Abstract

Carnosine (beta-alanyl-L-histidine) is an endogenous dipeptide synthesized via the activity of the ATP-dependent enzyme carnosine synthetase 1 and can be found at a very high concentration in tissues with a high metabolic rate, including muscles (up to 20 mM) and brain (up to 5 mM). Because of its well-demonstrated multimodal pharmacodynamic profile, which includes anti-aggregant, antioxidant, and anti-inflammatory activities, as well as its ability to modulate the energy metabolism status in immune cells, this dipeptide has been investigated in numerous experimental models of diseases, including Alzheimer's disease, and at a clinical level. The main limit for the therapeutic use of carnosine is related to its rapid hydrolysis exerted by carnosinases, especially at the plasma level, reason why the development of new strategies, including the chemical modification of carnosine or its vehiculation into innovative drug delivery systems (DDS), aiming at increasing its bioavailability and/or at facilitating the site-specific transport to different tissues, is of utmost importance. In the present review, after a description of carnosine structure, biological activities, administration routes, and metabolism, we focused on different DDS, including vesicular systems and metallic nanoparticles, as well as on possible chemical derivatization strategies related to carnosine. In particular, a basic description of the DDS employed or the derivatization/conjugation applied to obtain carnosine formulations, followed by the possible mechanism of action, is given. To the best of our knowledge, this is the first review that includes all the new formulations of carnosine (DDS and derivatives), allowing a decrease or complete prevention of the hydrolysis of this dipeptide exerted by carnosinases, the simultaneous blood-brain barrier crossing, the maintenance or enhancement of carnosine biological activity, and the site-specific transport to different tissues, which then offers perspectives for the development of new drugs.

摘要

肌肽(β-丙氨酰-L-组氨酸)是一种内源性二肽,通过ATP依赖性肌肽合成酶1的活性合成,在代谢率高的组织中浓度很高,包括肌肉(高达20 mM)和大脑(高达5 mM)。由于其已得到充分证明的多模式药效学特性,包括抗聚集、抗氧化和抗炎活性,以及调节免疫细胞能量代谢状态的能力,这种二肽已在包括阿尔茨海默病在内的众多疾病实验模型以及临床水平上进行了研究。肌肽治疗应用的主要限制与其被肌肽酶快速水解有关,尤其是在血浆水平,因此开发新策略至关重要,这些策略包括对肌肽进行化学修饰或将其装载到创新的药物递送系统(DDS)中,旨在提高其生物利用度和/或促进向不同组织的位点特异性转运。在本综述中,在描述了肌肽的结构、生物活性、给药途径和代谢后,我们重点关注了不同的DDS,包括囊泡系统和金属纳米颗粒,以及与肌肽相关的可能化学衍生化策略。特别是,给出了用于获得肌肽制剂的DDS或应用的衍生化/缀合的基本描述,以及可能的作用机制。据我们所知,这是第一篇涵盖肌肽所有新制剂(DDS和衍生物)的综述,这些制剂能够减少或完全防止肌肽酶对这种二肽的水解,同时穿过血脑屏障,维持或增强肌肽的生物活性,并实现向不同组织的位点特异性转运,从而为新药开发提供了前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75c9/10300694/8a7d0d5f5623/pharmaceuticals-16-00778-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验